Full Name: Parvovirus B19 IgG ELISA Kit
Sample Type: Serum
Sensitivity: diagn. 93%
Parvovirus B19 (B19V) is among some of the smallest single-stranded DNA virus that form part of the Parvoviridae (family) Erythrovirus (genus). It is found to infect only humans and display zero cross reactivity between animal parvoviruses and B19, thereby it is not to transmit this between humans and pets. The transmission B19V virus is through respiratory secretions, however, it is also known to be passed via bone marrow transplant, blood transfusion and to the baby from the mother via the placenta.
B19V is an infection which is found present as erythema infectiosum in children, other diseases which have also been associated with it include: meningitis, hepatitis, peripheral neuropathy, encephalitis and myocarditis.
Human parvovirus B19 IgG ELISA kit can be used for detecting levels of IgG class of antibodies against parvovirus B19 in serum sample. This assay has a minimum analytical sensitivity limit of diagn. 93%.
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Microtiterwells (96 wells): Wells coated with recombinant Parvovirus B19 antigen (VP1-s protein).
- Sample Diluent.
- Negative Control (Calibrator A).
- Cut-Off Control (Calibrator B).
- Positive Control (Calibrator C).
- Enzyme Conjugate.
- TMB Substrate Solution.
- Stop Solution: Contains 0.2 mol/L H2SO4.
- Wash Solution (20x Concentrated).
The minimum detection sensitivity level of human IgG antibodies to parvovirus B19 using current parvovirus IgG ELISA kit was diagn. 93%. The dynamic range for this assay was to a specific cut-off point.
– Positive: Mean OD patient > 1.2 × CO. [>12 DU]
– Grey Zone: 0.90 × CO ≤ Mean OD patient ≤ 1.2 × CO. [9 – 12 DU]
– Negative: Mean OD patient < 0.90 × CO. [<9 DU]
– Cut-Off: 10 DU
– Diagnostic Specificity: 100%
– Diagnostic Sensitivity: 98%
- Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG. Biologicals. (1997) 25 (3): 283-8. Ferguson M., et al.
- Increased seroprevalence of IgG-class antibodies against cytomegalovirus, parvovirus_B19, and varicella-zoster virus in women working in child day care. BMC Public Health. (2012) 12: 475. van Rijckevorsel G.G., et al.
- Comparative evaluation of tests for detection of parvovirus B19 IgG and IgM. APMIS. (2014) 122 (3): 223-9. de Ory F., et al.
- Intrauterine therapy for parvovirus-B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med. (2005) 33 (6): 561-3. Matsuda H., et al.
- Gender differences in the relationship of anti-parvovirus B19 IgG with antinuclear antibody and C-reactive protein in clinical adult serum samples. Rheumatol Int. (2010) 30 (4): 551-4. O’Bryan T.A. and Naides S.J.
OTHER RELATED ELISA KITS
Online Enquiry Form
"*" indicates required fields